Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) FCF Margin % : -12,612.90% (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Cyclacel Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cyclacel Pharmaceuticals's Free Cash Flow for the three months ended in Dec. 2023 was $-3.91 Mil. Cyclacel Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.03 Mil. Therefore, Cyclacel Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was -12,612.90%.

As of today, Cyclacel Pharmaceuticals's current FCF Yield % is -809.54%.

The historical rank and industry rank for Cyclacel Pharmaceuticals's FCF Margin % or its related term are showing as below:

CYCC' s FCF Margin % Range Over the Past 10 Years
Min: -4493.33 Med: -1195.97 Max: -745.58
Current: -3837.62

During the past 13 years, the highest FCF Margin % of Cyclacel Pharmaceuticals was -745.58%. The lowest was -4493.33%. And the median was -1195.97%.

CYCC's FCF Margin % is ranked worse than
86.34% of 1032 companies
in the Biotechnology industry
Industry Median: -148.935 vs CYCC: -3837.62

Cyclacel Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Cyclacel Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals FCF Margin % Chart

Cyclacel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-3,837.62

Cyclacel Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-349.87	-25,225.00	-12,612.90

Competitive Comparison of Cyclacel Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Cyclacel Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyclacel Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclacel Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cyclacel Pharmaceuticals's FCF Margin % falls into.

Cyclacel Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cyclacel Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-16.118	/	0.42
	=	-3,837.62 %

Cyclacel Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-3.91	/	0.031
	=	-12,612.90 %

Cyclacel Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (NAS:CYCC) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CYCCP.PFD:USA UXI:Germany

Address

200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922

Website

https://www.cyclacel.com

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Executives

Spiro Rombotis	director, officer: President & C.E.O.	C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Paul Mcbarron	director, officer: E.V.P., Finance & C.O.O.	C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Kenneth M. Ferguson	director	2125 1ST AVENUE #2902, SEATTLE WA 98121-2121
Sam L Barker	director	51 AUNT MOLLY ROAD, HOPEWELL NJ 08525
Brian Schwartz	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Karin L Walker	director	C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Mark Kirschbaum	officer: Chief Medical Officer	66 WEST 38TH STREET, APT. 19D, NEW YORK NY 10018
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Eastern Capital Ltd	10 percent owner	10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Kevin C Tang	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Portfolio Services Ltd.	10 percent owner	10 MARKET STREET, # 773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Kenneth Bryan Dart	10 percent owner	P. O. BOX 31300, GRAND CAYMAN E9 KY1-1206
Lloyd Sems	director	C/O SEMS CAPITAL, 7 DEY STREET, SUITE 1101, NEW YORK NY 10017